AstraZeneca's Perioperative Imfinzi 'Significantly Extends Survival' in Type of Bladder Cancer
AstraZeneca's Phase III NIAGARA study shows perioperative Imfinzi regimen significantly reduces risk of disease progression, recurrence, and death by 32% and 25% respectively in muscle-invasive bladder cancer patients, with no new safety signals.
Reference News
AstraZeneca's Perioperative Imfinzi 'Significantly Extends Survival' in Type of Bladder Cancer
AstraZeneca's Phase III NIAGARA study shows perioperative Imfinzi regimen significantly reduces risk of disease progression, recurrence, and death by 32% and 25% respectively in muscle-invasive bladder cancer patients, with no new safety signals.